Cardlytics CEO sells shares after RSU conversions
Cardlytics, Inc. director and CEO Amit Gupta reported a mix of RSU conversions and open-market sales of Common Stock.
Rhea-AI Filing Summary
Cardlytics, Inc. director and CEO Amit Gupta reported a mix of RSU conversions and open-market sales of Common Stock. On July 1, 2026, he converted 18,750 and 12,500 Restricted Stock Units into the same number of Common Stock shares at a conversion price of $0.00 per share. On July 2, 2026 and July 6, 2026, he then sold 6,498 and 9,640 Common Stock shares, respectively, at weighted average prices of about $4.40 per share. Following these transactions, Gupta directly holds 113,850 Common Stock shares. The filing notes a 1-for-10 reverse stock split effective June 5, 2026, and explains that RSU awards continue to vest in scheduled quarterly installments through April 1, 2027 and April 1, 2028, subject to ongoing employment.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 9,640 | $4.394 | $42K |
| Sale | Common Stock | 6,498 | $4.395 | $29K |
| Exercise | Restricted Stock Units | 12,500 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 18,750 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 18,750 | $0.00 | $0.00 |
Footnotes (6)
- F1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
- F2. Effective June 5, 2026, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.
- F3. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $4.260 to $4.540, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3).
- F4. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $4.280 to $4.510, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4).
- F5. 50% of the shares underlying the RSU award vested on April 1, 2026, with the remaining 50% vesting in equal amounts quarterly over a one-year period through April 1, 2027, provided that the Reporting Person remains employed by the Issuer on such vesting dates.
- F6. The RSU award will vest in equal amounts quarterly over a two-year period through April 1, 2028, provided that the Reporting Person remains employed by the Issuer on such vesting dates.
Key Figures
Key Terms
Restricted Stock Units financial
reverse stock split financial
weighted average sales price financial
vesting financial
derivative exercise/conversion financial
FAQ
What insider transactions did Cardlytics (CDLX) CEO Amit Gupta report?
What RSU activity is disclosed for Cardlytics (CDLX) CEO Amit Gupta?
How did Cardlytics’ June 2026 reverse stock split affect these Form 4 numbers?
What are the vesting schedules for the Cardlytics (CDLX) CEO’s RSU awards?
AI-generated analysis. How Rhea-AI works. Not financial advice.